Edition:
United States

Akers Biosciences Inc (AKER.OQ)

AKER.OQ on NASDAQ Stock Exchange Capital Market

0.37USD
4:00pm EDT
Change (% chg)

$0.00 (+0.49%)
Prev Close
$0.37
Open
$0.38
Day's High
$0.38
Day's Low
$0.37
Volume
144,595
Avg. Vol
956,465
52-wk High
$1.82
52-wk Low
$0.12

Chart for

About

Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including... (more)
No analyst recommendations are available for .

Overall

Beta: -1.01
Market Cap(Mil.): $32.55
Shares Outstanding(Mil.): 90.94
Dividend: --
Yield (%): --

Financials

  AKER.OQ Industry Sector
P/E (TTM): -- 212.74 32.86
EPS (TTM): -0.57 -- --
ROI: -92.87 -3.73 13.13
ROE: -108.04 -5.79 15.07

BRIEF-Akers Biosciences Files Non Timely 10-Q - SEC Filing

* AKERS BIOSCIENCES INC FILES NON TIMELY 10-Q - SEC FILING Source text: (https://bit.ly/2k6a2jr) Further company coverage:

May 16 2018

BRIEF-Akers Biosciences Says Terminated Raymond Akers Positions As Executive Chairman

* SAYS TERMINATED RAYMOND AKERS POSITIONS AS EXECUTIVE CHAIRMAN, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY

Apr 26 2018

BRIEF-Akers Biosciences Says Appointed Richard Carlyle Tarbox III As Interim Non-Executive Chairman

* AKERS BIOSCIENCES - BOARD TERMINATED RAYMOND AKERS FROM POSITION AS EXECUTIVE CHAIRMAN OF BOARD, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY

Apr 25 2018

BRIEF-Akers Biosciences Expands Outsourced U.S. Distribution Capabilities For Heparin PF4 Rapid Test

* AKERS BIOSCIENCES EXPANDS OUTSOURCED US DISTRIBUTION CAPABILITIES FOR HEPARIN PF4 RAPID TEST

Apr 12 2018

BRIEF-Akers Biosciences Reports Earnings For Fiscal Year 2017

* AKERS BIOSCIENCES REPORTS EARNINGS FOR FISCAL YEAR 2017 Source text for Eikon: Further company coverage:

Apr 03 2018

BRIEF-Akers Biosciences Signs Distribution Agreement With Diagnostica Stago

* AKERS BIOSCIENCES SIGNS US DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO

Mar 26 2018

BRIEF-Akers Biosciences Announces Distribution Agreement With Diagnostica Stago​

* ‍ENTERED INTO 3-YEAR DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO FOR SALE OF CO'S RAPID TEST FOR HEPARIN-INDUCED THROMBOCYTOPENIA ACROSS US​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Mar 26 2018

Earnings vs. Estimates